Internal Medicine, Hematology & Oncology · Langhorne, PA
NPI
1124178819
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1203 Langhorne Newtown Rd, Suite 135
Langhorne, PA, 19047
Phone (215) 750-5050
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
106,779 services
Medicare patients, 2024
580
Average age 75
Drug cost, 2024
$2.0M
1,131 prescriptions
Company payments, 2025
$3,377
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert E Reilly was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 10,770 times for 11 patients. In total Robert E Reilly billed 106,779 services in 113 codes, and Medicare paid $1.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-09-22.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 10,770 | 11 | $2.27 | $24K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 8,400 | 17 | $0.11 | $934 |
| J0897 Injection, denosumab, 1 mg | Office | 7,740 | 47 | $20.62 | $160K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,200 | 34 | $15.72 | $66K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 4,110 | 15 | $5.70 | $23K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,696 | 18 | $20.82 | $77K |
| 36415 Venipuncture Blood Collection | Office | 1,342 | 357 | $8.65 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,226 | 36 | $0.09 | $110 |
| 85025 Blood Count | Office | 945 | 270 | $7.58 | $7,164 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 830 | 28 | $0.71 | $591 |
| 99213 Office E&M - Established | Office | 675 | 360 | $70.60 | $48K |
| 96375 Injection Administration | Office | 414 | 87 | $13.22 | $5,471 |
| 96372 Injection Administration | Office | 401 | 97 | $12.17 | $4,881 |
| 99214 Office E&M - Established | Office | 368 | 168 | $103.99 | $38K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 301 | 221 | $13.63 | $4,103 |
By year: 2022 $2.6M for 169,454 services; 2023 $2.2M for 116,452 services; 2024 $1.8M for 106,779 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,342 | 357 | $8.65 | $12K |
| 85025 Blood Count | 945 | 270 | $7.58 | $7,164 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert E Reilly prescribed most often to Medicare patients was Anastrozole, with 207 prescriptions and refills. In total Robert E Reilly wrote 1,131 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 207 | 498 | 70 | $5,846 |
| Tamoxifen Citrate Generic | 135 | 241 | 28 | $3,531 |
| Eliquis Apixaban | 88 | 106 | 22 | $60K |
| Letrozole Generic | 73 | 133 | 21 | $997 |
| Hydroxyurea Generic | 38 | 72 | 13 | $1,020 |
| Xarelto Rivaroxaban | 33 | 47 | Under 11 | $25K |
| Compro Prochlorperazine | 26 | 26 | Under 11 | $4,427 |
| Dexamethasone Generic | 24 | 25 | Under 11 | $400 |
| Exemestane Generic | 23 | 57 | Under 11 | $3,005 |
| Ondansetron Odt Ondansetron | 23 | 23 | 20 | $215 |
| Prednisone Generic | 23 | 24 | 12 | $105 |
| Gabapentin Generic | 20 | 31 | Under 11 | $208 |
| Alprazolam Generic | 19 | 19 | Under 11 | $67.07 |
| Oxycodone Hcl Generic | 18 | 19 | Under 11 | $238 |
| Jakafi Ruxolitinib Phosphate | 16 | 16 | Under 11 | $266K |
Brand drugs: 257 claims; generic drugs: 874 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert E Reilly $3,377 ($3,377 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $237.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 11 | $237 |
| Incyte Corporation INCY | 15 | $234 |
| Janssen Biotech, Inc. JNJ | 12 | $198 |
| Daiichi Sankyo Inc. 4568.T | 8 | $195 |
| Abbvie Inc. ABBV | 9 | $187 |
| Merck Sharp & Dohme LLC MRK | 6 | $173 |
| GlaxoSmithKline, LLC. GSK | 7 | $157 |
| Genmab U.S., Inc. GMAB | 6 | $154 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $153 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $134 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.